Stratec SE · XETR:SBS

Stratec — Investor Presentation (November 2026)

26 slides from Stratec's investor presentation, November 2026

  1. Slide 1: IR Presentation November 2026

    IR PRESENTATION November 2026

  2. Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realis

  3. Slide 3: STRATEC at a Glance

    STRATEC AT A GLANCE  Leading OEM player for automation solutions for the diagnostics industry and translational research  Three decades of experience in highly regulated healthcare markets and growing technology pool  Around 1,400 employees worldwide  Around 50% allocable to R&D  Production sit

  4. Slide 4: Unique Position Within the Value Chain

    UNIQUE POSITION WITHIN THE VALUE CHAIN Shared responsibilities STRATEC provides instrumentation, consumables, software and automation solutions Analyzer Market  OEM development and manufacturing Partner Systems Access  Several thousand automated analyzer systems manufactured annually  Wide range

  5. Slide 5: Active in Fast Growing Segments

    ACTIVE IN FAST GROWING SEGMENTS IVD MARKET SEGMENTS / IVD MARKET: ~90 BILLION USD IVD market by technologies Focus on market segments with above-average complexity and growth Molecular Diagnostics  Random access analyzer systems (mid-to-high throughput)  Smart consumables (multiplexing)  POC devi

  6. Slide 6: Benefitting from Outsourcing Trend

    BENEFITTING FROM OUTSOURCING TREND OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET Outsourcing to specialized players set to continue, due to: The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics Engineering of automation solutions often not a core com

  7. Slide 7: Strong Recurring Revenue Base

    STRONG RECURRING REVENUE BASE Service parts and consumables  41% of sales Smart consumables Service and spare parts  Maintenance parts  Spare parts  Classic plastic consumables (eg. Pipetting tips, reaction vessels) Peristaltic Pump  Smart consumables (highly complex cartridges; microfluidics,

  8. Slide 8: Strong Long-Term Customer Relationships

    STRONG LONG-TERM CUSTOMER RELATIONSHIPS A SELECTION OF STRATEC CUSTOMERS Sales 2025 Sales 2025 15 # Global top 20 IVD companies (USD bn) # Global top 20 IVD companies (USD bn) 1 Roche 16.9 11 Illumina 2.3 2 Danaher 9.9 12 Natera 2.3 of the global top 20 IVD companies are STRATEC customers 3 Abbott 8

  9. Slide 9: Global Set Up Aligned with Customers

    GLOBAL SET UP ALIGNED WITH CUSTOMERS LOCATIONS OF THE STRATEC GROUP Site overview Birkenfeld, Germany Budapest, Hungary Anif, Austria Beringen, Switzerland HQ, R&D, Instrumentation Instrumentation Production, R&D, Consumables Production, Instrumentation Production Production, Sales Sales Sales Cluj,

  10. Slide 10: Sharpening the Focus on Core Businesses

    DIATRON TRANSACTION SHARPENING THE FOCUS ON CORE BUSINESSES Scope Rationale Financials • Agreement with a consortium of Indian • Focus • Fixed purchase price of € 10.0 million investors signed on October 30, 2026 On core business: Fully integrated and plus potential earn-out payments automated syste

  11. Slide 11: Highlights and Achievements

    9M AND Q3 2026 AT A GLANCE HIGHLIGHTS AND ACHIEVEMENTS Growth in core system Continued strong 2026 guidance for Pipeline progress lines profitability in Q3 continuing operations • Double-digit growth in 9M • Significant margin gain and • Notable pick up of customers • Improved visibility on a strong

  12. Slide 12: Financials at a Glance 9M 2026

    FINANCIAL REVIEW FINANCIALS AT A GLANCE 9M 20261 € 000s 9M/2026 9M/2025 Change Q3/2026 Q3/2025 Change -6.1% -8.1% Sales 164,907 175,588 52,371 56,998 (cc: -5,0%) (cc: -8.7%) Adjusted EBITDA 25,304 24,235 +4.4% 9,614 8,165 +17.7% Adjusted EBITDA margin (%) 15.3 13.8 +150 bps 18.4 14.3 +410 bps Adjust

  13. Slide 13: Adjustments 9M 2026

    FINANCIAL REVIEW ADJUSTMENTS 9M 2026 EBIT Consolidated net income € 000s 9M 2026 9M 2025 € 000s 9M 2026 9M 2025 Adjusted EBIT 13,657 12,824 Adjusted consolidated net income 7,509 7,104 Adjustments: Adjusted earnings per share in € (basic) 0.62 0.58 PPA amortization -1,388 -2,309 Adjustments: Write-d

  14. Slide 14: Sales 9M 2026

    FINANCIAL REVIEW SALES 9M 2026 9M 2026 sales -5.0% yoy in constant currency to € 164.9 million (nominal: -6.1%) € 175.6 -5.0% at cc € 164.9 million YoY million • Double-digit growth with immunoassay and molecular diagnostics systems • Decline in service parts and consumables sales due to logistics o

  15. Slide 15: Adjusted EBIT and EBIT Margin 9M 2026

    FINANCIAL REVIEW ADJUSTED EBIT AND EBIT MARGIN 9M 2026 9M 2026 adj. EBIT at € 13.7 million Margin with 8.3% above prior year’s level • Efficiency measures and structural changes +6.5% € 13.7 € 12.8 YoY • Product mix million million • FX Margin Margin +100 bps 8.3% 7.3% YoY • Decreased share of high-

  16. Slide 16: Cash Flow and Net Debt

    FINANCIAL REVIEW CASH FLOW AND NET DEBT € 000s 9M 2026 9M 2025 Change Strong cash flow dynamics driven by strict working capital management and reduction in elevated trade receivables following the Cash flow – operating activities 39,386 -1,435 n/a strong year-end business in 2025 Cash flow – invest

  17. Slide 17: Sales by Operating Divisions H1 2026

    FINANCIAL REVIEW SALES BY OPERATING DIVISIONS H1 2026 Sales in € million In % of total sales 60 -14.1% (-11.9% at cc) 100% 50 +13.7% 29.5% 80% 35.3% (+15.4% at cc) 40 -9.0% (-7.8% at cc) 60% 30 53.7 45.3% 46.1 41.0% 20 40% 39.7 34.9 28.8 26.2 -56.2% 10 20% (-56.2% at cc) 24.2% 1.2 0.5 23.2% 0 0% Sys

  18. Slide 18: Financial Guidance for Fiscal Year 2026

    OUTLOOK FINANCIAL GUIDANCE FOR FISCAL YEAR 20261 CONSOLIDATED SALES ADJUSTED EBIT MARGIN INVESTMENTS2 Stable to slightly higher 13.0% - 15.0% 5.0% - 7.0% at constant-currency and based on pro- (excluding Diatron business sold; accounted of sales for tangible and intangible assets forma sales of € 22

  19. Slide 19: Improving Visibility on Expected Strong Year-End

    OUTLOOK IMPROVING VISIBILITY ON EXPECTED STRONG YEAR-END Restated figures to account for Diatron business sold as Required sales volume for Q4 2026 to achieve midpoint of FY 2026 discontinuing operation: sales guidance: € 000s 9M/2026 9M/2025 Sales 151,750 157,391 Adjusted EBIT 20,269 17,152 ~ € 76.

  20. Slide 20: Focus in 2026 and Beyond

    OUTLOOK FOCUS IN 2026 AND BEYOND 01 02 03 Maintaining cost discipline Comprehensive and timely transfer Fulfilment of high manufacturing throughout the company of newly developed systems into series production, volumes foreseen for the remainder of the year ensuring foreseen quality 04 05 06 Execute

  21. Slide 21: Launch Pipeline & Market Dynamics

    OUTLOOK LAUNCH PIPELINE & MARKET DYNAMICS UPCOMING LAUNCH PIPELINE IVD MARKET TRENDS BY APPLICATION Next-generation immunoassay system Overall IVD market: low to mid single-digit growth rates Fully automated; extends addressable market for customer due to wider throughput range; drop-in replacement

  22. Slide 22: Corporate Social Responsibility

    CORPORATE SOCIAL RESPONSIBILITY Ecological Corporate Social responsibility responsibility governance AS A BASIS FOR TRUST AND FOR A BETTER TOMORROW TOWARDS PEOPLE AND SOCIETY TRANSPARENCY • Global Environmental Policy outlines • Strong policies and measures to promote • Compliance management system

  23. Slide 23: Appendix

    f stratecee AP PENDIX

  24. Slide 24: Key Figures at a Glance

    APPENDIX KEY FIGURES AT A GLANCE1 IFRS (€ million) 2020 2021 2022 2023 2024 2025 Sales 250.1 287.3 274.6 270.4 257.6 250.9 Adjusted EBIT 41.7 54.3 45.1 30.4 33.5 25.2 Adjusted EBIT margin (%) 16.7 18.9 16.4 11.2 13.0 10.0 Adjusted consolidated net income 35.2 45.1 34.7 19.0 20.5 14.2 Adjusted earnin

  25. Slide 25: Shareholder Structure

    APPENDIX SHAREHOLDER STRUCTURE (AS OF MAY 2026) SHARE IPO Aug. 1998 Number of shares 12,157,841 Share price (2026-11-12) € 26.25 Market capitalization € 319 million Institutional investors > 10%¹ Briarwood Capital Partners (Aalap Mahadevia) · Morgan Stanley Institutional investors > 3%¹ Brown Capita

  26. Slide 26: Thank You for Your Attention

    CONTACT STRATEC SE THANK YOU Gewerbestr. 37 75217 Birkenfeld FOR YOUR Germany ATTENTION Phone +49 7082 7916-0 Fax +49 7082 7916-999 www.stratec.com CONTACT Jan Keppeler, CFA Head of Investor Relations, Sustainability & Corporate Communications Phone +49 7082 7916-6515 j.keppeler@stratec.com 26

Stratec — Investor Presentation (November 2026) on 6ix